Piper Sandler raised the firm’s price target on ShockWave Medical to $290 from $275 and keeps an Overweight rating on the shares. ShockWave reported a top line beat in Q4, with EPS well ahead of expectations, and guidance for fiscal 2024 revenue comfortably brackets the Street’s estimates, the analyst tells investors in a research note. The firm likes the set-up for the stock particularly entering the second half of 2024, and ranks ShockWave as the top SMID cap name from its list.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SWAV:
- Shockwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results
- SWAV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Shockwave Medical Announces Regulation FD Disclosure Update
- Shockwave Medical Names Renee Gaeta New CFO
- Shockwave Medical Appoints Renee Gaeta as Chief Financial Officer
